Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

After a few years of stagnation, this stock is soaring.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is ...

The stock of Moderna (MRNA) is surging in value today, up over 135% in value at the time of writing, to $150 per share - a three-and-a-half-year high, reflecting a market cap valuation of ~$25bn.

Moderna (NASDAQ:MRNA) joins the Nasdaq-100, appoints an operating chief and prepares individualized cancer therapy data for a major congress.

A personalized messenger RNA cancer treatment developed by Moderna and Merck enabled melanoma patients to live longer without signs of their disease coming back, results the companies say mark the ...

Pfizer, BioNTech and Moderna lose bids to dismiss Bayer patent lawsuits alleging their COVID-19 vaccines use ...

Moderna’s dramatic ascent this year has been fueled by optimism that its personalized cancer vaccine could reshape oncology and redefine the company beyond its pandemic-era success. That promise may ...

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

Add Yahoo as a preferred source to see more of our stories on Google. The FDA on Aug. 5, 2026 approved a new mRNA-based flu vaccine. (Melissa Phillip/AP) After months of regulatory questioning, the ...